Allspring Global Investments Holdings LLC Sells 741 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Allspring Global Investments Holdings LLC lessened its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 6.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,010 shares of the company’s stock after selling 741 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Castle Biosciences were worth $285,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. RiverPark Advisors LLC raised its holdings in Castle Biosciences by 362.2% in the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after acquiring an additional 2,242 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Castle Biosciences by 10.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after acquiring an additional 952 shares during the period. XTX Topco Ltd bought a new position in Castle Biosciences in the 2nd quarter worth $218,000. The Manufacturers Life Insurance Company raised its holdings in Castle Biosciences by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after acquiring an additional 675 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Castle Biosciences during the 1st quarter worth about $249,000. Institutional investors own 92.60% of the company’s stock.

Insiders Place Their Bets

In other Castle Biosciences news, insider Derek J. Maetzold sold 986 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $28.73, for a total transaction of $28,327.78. Following the sale, the insider now directly owns 94,622 shares of the company’s stock, valued at approximately $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Frank Stokes sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $25.70, for a total transaction of $257,000.00. Following the transaction, the chief financial officer now directly owns 30,823 shares in the company, valued at approximately $792,151.10. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Derek J. Maetzold sold 986 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $28.73, for a total transaction of $28,327.78. Following the transaction, the insider now owns 94,622 shares in the company, valued at $2,718,490.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,694 shares of company stock valued at $820,497. 7.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. BTIG Research upped their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Canaccord Genuity Group upped their price objective on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Robert W. Baird upped their price objective on shares of Castle Biosciences from $34.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, August 6th. Finally, Stephens reaffirmed an “overweight” rating and set a $37.00 price objective on shares of Castle Biosciences in a research report on Tuesday, August 6th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $35.14.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $33.15 on Friday. The stock has a market cap of $915.17 million, a P/E ratio of -236.79 and a beta of 0.98. The company’s 50-day simple moving average is $30.57 and its 200 day simple moving average is $25.44. Castle Biosciences, Inc. has a twelve month low of $16.14 and a twelve month high of $35.42. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, August 5th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.47. The business had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. As a group, research analysts forecast that Castle Biosciences, Inc. will post -0.58 earnings per share for the current fiscal year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.